These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Emerging disease-modifying oral therapies for multiple sclerosis.
    Author: Losy J, Kalinowska-Łyszczarz A.
    Journal: J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176.
    Abstract:
    Although therapy for multiple sclerosis (MS) has changed substantially over the past few decades, introducing immunomodulatory drugs into everyday clinical practice, it is still not satisfactory enough in halting the disease progression and increasing disability. Moreover, its injection-based administration leads to suboptimal adherence, even further reducing the potential treatment benefits. Emerging disease-modifying oral agents for MS are therefore warranted. In this paper advances in the novel oral therapeutic approaches to MS treatment are reviewed.
    [Abstract] [Full Text] [Related] [New Search]